Migraine - Global Drug Forecast and Market Analysis to 2023

293 views

Published on

Market Research Reports, Inc. has announced the addition of “PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023” research report to their offering. See more at- http://mrr.cm/ZQQ

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
293
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Migraine - Global Drug Forecast and Market Analysis to 2023

  1. 1. www.MarketResearchReports.com Category : Pharma & Healthcare All logos and Images mentioned on this slide belong to their respective owners.
  2. 2. www.MarketResearchReports.com Introduction to Report  Launch Date: March 31, 2014  Number of Pages: 278  Geography Coverage: Global  Available Format: PDF Price For Single User License: USD 9,995 Price For Site License: USD 1,990 Price For Global User License: USD 29,985 Delivery Time: Within 24 Hours (During Working Days)
  3. 3. www.MarketResearchReports.com About the Report The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population.
  4. 4. www.MarketResearchReports.com Research Findings The global migraine treatment market value is expected to undergo a modest increase over the coming years, climbing from $2.5 billion in 2012 to $3.7 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 3.6%, according to a new report from research and consulting firm by Publisher. The company’s latest report states that out of the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan), the US dominated the migraine space in 2012 with a global share of 77%. It will maintain its market-leading position by 2023, with a higher share of 84%. Teva and NuPathe’s Zecuity, the first and only iontophoretic transdermal system for migraine, will prove popular among the population that requires or prefers an alternative route of administration over the existing formulations of acute treatments. We expect the therapy to achieve sales of approximately $180.5 million by 2023. We forecast that CoLucid’s lamiditan and Merck’s MK-1602 combined sales will reach nearly $1.3 billion by 2023
  5. 5. www.MarketResearchReports.com Research Findings Continues.. The main driver of the expansion of the migraine market will be the continuous use of Botox for chronic migraine. The introduction of reformulations of mature products as well as new classes of therapies will further increase the market size. The biggest barrier for the introduction of new therapies will be patent expirations of the majority of the drugs marketed for migraine, which have resulted in an increase of generics, and which may negatively impact revenue from branded drugs that are expected to launch in the forecast period. The concerns of reducing healthcare costs as part of government austerity measures, particularly in Europe, which will impede market growth. To ensure reimbursement companies will have to work closely together with payers and price their drugs competitively.
  6. 6. www.MarketResearchReports.com Report Coverage 1. Introduction 2. Disease Overview 3. Epidemiology 4. Disease Management 5. Competitive Assessment 6. Opportunity and Unmet Need 7. Pipeline Assessment 8. Current and Future Players 9. Market Outlook 10.Appendix For more details regarding Report coverage see the last slide All logos and Images mentioned on this slide belong to their respective owners.
  7. 7. www.MarketResearchReports.com Company Coverage 1. GlaxoSmithKline 2. AstraZeneca 3. Merck 4. Vernalis 5. Almirall 6. Pfizer 7. Zogenix 8. NuPathe 9. Allergan 10.RedHill Biopharma 11.OptiNose 12.CoLucid Pharmaceuticals 13.SUDA 14.Revance Therapeutics 15.NeurAxon For more details regarding Report coverage see the last slide All logos and Images mentioned on this slide belong to their respective owners.
  8. 8. www.MarketResearchReports.com Custom Research:  Are you an industry professional, entrepreneur, venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research. For Any Customization Related query Visit IdeaCenter @ http://www.marketresearchreports.com/idea-center
  9. 9. www.MarketResearchReports.com How To Buy This Report? Visit following URL to see Table of Content and purchase this publication: http://mrr.cm/ZQQ About Market Research Reports, Inc. Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”. Contact : Amitava Sen Email : info@marketresearchreports.com Phone: +1 302-703-7787 (USA) +91-8762746600 (India)

×